Anupam Rasayan India Ltd is expected to file its formal open offer documentation with the Securities and Exchange Board of India (SEBI) on Tuesday, triggering the next regulatory phase of its planned acquisition of a 43.3% to 48.2% equity stake in Mumbai-based Bliss GVS Pharma Ltd. The transaction, announced in the days prior, marks the specialty chemicals company's strategic pivot into the pharmaceutical sector — a move that has drawn both interest and scepticism from equity analysts tracking the mid-cap Indian market.
Under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, Anupam Rasayan is obligated to make an open offer to Bliss GVS Pharma's public shareholders once its direct stake acquisition crosses the 25% threshold. The open offer is expected to be priced at a premium to the prevailing market rate, with Kotak Mahindra Capital or a comparable investment bank acting as manager to the offer — a standard requirement under Indian securities law for transactions of this scale.
Bliss GVS Pharma, which manufactures generic pharmaceutical formulations and has a significant presence in African export markets, provides Anupam Rasayan with immediate revenue diversification away from agrochemicals and fine chemicals. Analysts at brokerages including Motilal Oswal and ICICI Securities are expected to initiate or revise coverage of Anupam Rasayan on Tuesday, with several flagging execution risk given the cultural and operational distance between specialty chemicals and pharmaceutical manufacturing.
Shares of Bliss GVS Pharma have already seen elevated trading volumes since the initial announcement, and market participants will watch closely on Tuesday for any counter-bid or competing interest from other pharmaceutical consolidators. The Indian pharma mid-cap space has seen rising M&A activity in 2026, with larger generic players seeking bolt-on acquisitions to expand their African and Southeast Asian distribution networks — the same geography where Bliss GVS has established footholds.
Anupam Rasayan's management is expected to address investor concerns in a post-announcement call or exchange filing, clarifying synergy targets and the timeline for operational integration. The company's stock has faced pressure since the deal was disclosed, reflecting market uncertainty about the strategic rationale, and Tuesday's regulatory filings and any accompanying management commentary will be closely watched as a gauge of institutional confidence in the transaction.